----YOU ADS---
----YOU ADS---
----YOU ADS---
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
----YOU ADS---